774
Views
1
CrossRef citations to date
0
Altmetric
Articles

S100A9/CD163 Expression in Circulating Classical Monocytes in Chronic Obstructive Pulmonary Disease

ORCID Icon, &
Pages 587-594 | Received 18 Jan 2020, Accepted 06 Jul 2020, Published online: 23 Sep 2020

Figures & data

Table 1. Patient characteristics.

Figure 1. Representative flow cytometric analyses for peripheral blood circulating monocytes. Cells obtained from the peripheral blood monocytes (PBMCs) were used for analyses, and doublets and debris were excluded. Representative plots illustrate the gating strategy in samples obtained from COPD patients. (Top). CD14+CD16—classical monocytes, CD14+CD16+—intermediate monocytes, and CD14diminishCD16+—alternative monocytes were identified. (Bottom left and right). Dot plots represent isotype controls and primary antibodies against S100A9 and CD163 in classical monocytes.

Figure 1. Representative flow cytometric analyses for peripheral blood circulating monocytes. Cells obtained from the peripheral blood monocytes (PBMCs) were used for analyses, and doublets and debris were excluded. Representative plots illustrate the gating strategy in samples obtained from COPD patients. (Top). CD14+CD16−—classical monocytes, CD14+CD16+—intermediate monocytes, and CD14diminishCD16+—alternative monocytes were identified. (Bottom left and right). Dot plots represent isotype controls and primary antibodies against S100A9 and CD163 in classical monocytes.

Table 2. Impact of background factors on cell polarization of circulating classical monocytes.

Figure 2. Rates of S100A9+ and CD163+ circulating classical monocytes in three groups. (A). Rates of S100A9+ monocytes (Gate 1 + 2). (B). Rates of S100A9+CD163 monocytes (Gate 1). (C). Rates of S100A9+CD163+ monocytes (Gate 2). (D). Rates of CD163+ monocytes (Gate 2 + 4). (E). Rates of S100A9CD163+ monocytes (Gate 4). (F). Ratios of S100A9+/CD163+ monocytes (Gate 1/Gate 4). LFT: lung function tests. p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Figure 2. Rates of S100A9+ and CD163+ circulating classical monocytes in three groups. (A). Rates of S100A9+ monocytes (Gate 1 + 2). (B). Rates of S100A9+CD163− monocytes (Gate 1). (C). Rates of S100A9+CD163+ monocytes (Gate 2). (D). Rates of CD163+ monocytes (Gate 2 + 4). (E). Rates of S100A9−CD163+ monocytes (Gate 4). (F). Ratios of S100A9+/CD163+ monocytes (Gate 1/Gate 4). LFT: lung function tests. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Figure 3. Receiver operating characteristic (ROC) curve analysis to assess the diagnostic validity of the ratio of S100A9+CD163/S100A9CD163+ cells in circulating classical monocytes in discriminating COPD patients from current smokers with normal lung functions. The area under the curve (AUC) was 0.719 (p < 0.01, 95% confidence interval [CI] = 0.567–0.871) for the diagnoses of COPD.

Figure 3. Receiver operating characteristic (ROC) curve analysis to assess the diagnostic validity of the ratio of S100A9+CD163−/S100A9−CD163+ cells in circulating classical monocytes in discriminating COPD patients from current smokers with normal lung functions. The area under the curve (AUC) was 0.719 (p < 0.01, 95% confidence interval [CI] = 0.567–0.871) for the diagnoses of COPD.

Table 3. Univariate and multivariate logistic regression analyses for COPD diagnoses discriminating from smokers with normal lung functions.

Table 4. Specificity, sensitivity, and threshold values of each parameter with area under the receiver operating characteristic.

Supplemental material

Supplemental Material

Download PDF (984.3 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.